title: The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.
abstract: Patients undergoing primary myocardial revascularization were randomized to one of three drug regimens (low-dose aprotinin, epsilon-aminocaproic Acid or tranexamic Acid) to determine which drug regimen would most effectively reduce post-operative bleeding and the need for blood products. All patients had received 325 mg of aspirin within 48 h before operation. All three drug regimens reduced the requirements for blood products and postoperative bleeding after coronary artery bypass operations. There was, however, no significant difference between drug regimens.
authors.forename: R W
authors.initials: RW
authors.lastname: Landymore
authors.forename: J T
authors.initials: JT
authors.lastname: Murphy
authors.forename: H
authors.initials: H
authors.lastname: Lummis
authors.forename: C
authors.initials: C
authors.lastname: Carter
mesh_terms: D015119:Aminocaproic Acid / Q000008:administration & dosage*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage*; D007611:Aprotinin / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D001026:Coronary Artery Bypass; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019106:Postoperative Hemorrhage / Q000097:blood / Q000517:prevention & control*; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D007611:Aprotinin; D001241:Aspirin; D015119:Aminocaproic Acid